
US FDA Declines Novocure Device
The US Food and Drug Administration has declined to approve Novocure's device for lung cancer patients with brain metastases. The agency cited uncertainty regarding clinical benefit, though no safety concerns were raised.
Xurve View
Insights:
Xurve View

Novocure declined 12% on Monday after the United States Food and Drug Administration rejected its lung cancer therapy device. The regulatory setback halts commercial expansion plans for the company's flagship oncology portfolio. Investors now face delayed revenue streams as management weighs whether to launch expensive new clinical trials.








